- Report
- February 2026
- 506 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- May 2025
- 136 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- June 2025
- 150 Pages
Global
From €2364EUR$2,699USD£2,052GBP
- Report
- May 2024
- 139 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- May 2024
- 130 Pages
Global
From €3502EUR$3,999USD£3,040GBP
Mirapex (pramipexole dihydrochloride) is a centrally acting dopamine agonist used to treat the symptoms of Parkinson's disease and restless legs syndrome. It is a member of the non-ergoline dopamine agonist class of drugs, which are used to treat Parkinson's disease and other movement disorders. Mirapex works by stimulating dopamine receptors in the brain, which helps to reduce the symptoms of Parkinson's disease and restless legs syndrome. It is available in both immediate-release and extended-release formulations.
Mirapex is a popular drug in the Central Nervous System (CNS) drug market. It is used to treat a variety of neurological conditions, including Parkinson's disease, restless legs syndrome, and other movement disorders. It is also used to treat depression and anxiety. Mirapex is generally well-tolerated and has few side effects.
Some companies in the Mirapex market include Pfizer, Merck, GlaxoSmithKline, and Novartis. Show Less Read more